Figure 3From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study Objective tumor responses. Objective responses documented in a prostate cancer patient treated at 50 mg dose and a breast cancer patient treated at 40 mg dose.Back to article page